Dr Reddy's inks licensing pact with Eli Lilly for COVID-19 treatment drug

Dr Reddy's inks licensing pact with Eli Lilly for COVID-19 treatment drug

PTIUpdated: Tuesday, May 11, 2021, 11:00 PM IST
article-image
Health workers wearing personal protective equipment (PPE kit) attend to Covid-19 coronavirus patients inside a banquet hall temporarily converted into a Covid care centre in New Delhi on May 7, 2021/ File | (Photo by AFP)

Dr Reddy's Laboratories on Tuesday said it has inked a licensing pact with Eli Lilly and Company to produce Baricitinib in the country for treatment of COVID-19.

The Hyderabad-based firm said it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialisation of the drug in India.

Baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organisation (CDSCO) for use in combination with remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company's existing range of COVID-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine, Dr Reddy's noted.

"From the start, we have been determined to explore every possible avenue against COVID-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India," Dr Reddy's Laboratories CEO (API and Services) Deepak Sapra said.

On May 10, Eli Lilly and Company had announced voluntary licensing agreements with Sun Pharma, Cipla and Lupin to expedite the availability of its arthritis drug Baricitinib for treatment of COVID-19 patients in India.

RECENT STORIES

India’s Festive Season To Create Over 2.16 Lakh Jobs In H2 2025, Driven B Retail, E-commerce And...

India’s Festive Season To Create Over 2.16 Lakh Jobs In H2 2025, Driven B Retail, E-commerce And...

Gold Drops ₹500 Amid Stockist Selling, Silver Falls ₹1,000 Despite Global Gains

Gold Drops ₹500 Amid Stockist Selling, Silver Falls ₹1,000 Despite Global Gains

Tech Mahindra Q1 FY26 Net Profit Rises 33.9% To ₹1,140.6 Crore; Revenue Grows Marginally To...

Tech Mahindra Q1 FY26 Net Profit Rises 33.9% To ₹1,140.6 Crore; Revenue Grows Marginally To...

Govt Approves ₹20,000 Crore Investment Power For NTPC To Add 60 GW Green Energy By 2032

Govt Approves ₹20,000 Crore Investment Power For NTPC To Add 60 GW Green Energy By 2032

Telecom Operator MTNL Defaults On ₹8,585 Crore Loans to 7 PSU Banks

Telecom Operator MTNL Defaults On ₹8,585 Crore Loans to 7 PSU Banks